Matriptase-2 gene (TMPRSS6) variants associate with breast cancer survival, and reduced expression is related to triple-negative breast cancer

International Journal of Cancer

Volumn 133, Issue 10, 2013, Pages 2334-2340

  Tuhkanen, Hanna ^a,b   Hartikainen, Jaana M ^a,b   Soini, Ylermi ^a,b   Velasco, Gloria ^c   Sironen, Reijo ^a,b   Nykopp, Timo K ^a,b   Kataja, Vesa ^a,b   Eskelinen, Matti ^b   Kosma, Veli Matti ^a,b   Mannermaa, Arto ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

Author keywords

breast cancer; expression; genetic variation; matriptase 2; survival

Indexed keywords

DNA; MATRIPTASE 2; RNA; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CANCER GRADING; CANCER RISK; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RNA ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE MICROARRAY; TMPRSS6 GENE; TRIPLE NEGATIVE BREAST CANCER; TUMOR GENE; TUMOR GROWTH;

BREAST CANCER; EXPRESSION; GENETIC VARIATION; MATRIPTASE-2; SURVIVAL;

ALLELES; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; GENOTYPE; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK; SERINE ENDOPEPTIDASES; SURVIVAL RATE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84883790186     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28254     Document Type: Article

References (40)

1. Hooper JD, Clements JA, Quigley JP, et al. Type II transmembrane serine proteases: insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem 2001; 276: 857-60.
2. Velasco G, Cal S, Quesada V, et al. Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins. J Biol Chem 2002; 277: 37637-46.
3. Du X, She E, Gelbart T, et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science 2008; 320: 1088-92.
4. Folgueras AR, de Lara FM, Pendas AM, et al. Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis. Blood 2008; 112: 2539-45.
5. Meynard D, Vaja V, Sun CC, et al. Regulation of TMPRSS6 by BMP6 and iron in human cells and mice. Blood 2011; 118: 747-56.
6. Finberg KE, Heeney MM, Campagna DR, et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 2008; 40: 569-71.
7. Melis MA, Cau M, Congiu R, et al. A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica 2008; 93: 1473-9.
8. Guillem F, Lawson S, Kannengiesser C, et al. Two nonsense mutations in the TMPRSS6 gene in a patient with microcytic anemia and iron deficiency. Blood 2008; 112: 2089-91.
9. Silvestri L, Pagani A, Nai A, et al. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 2008; 8: 502-11.
10. Maxson JE, Chen J, Enns CA, et al. Matriptase-2- and proprotein convertase-cleaved forms of hemojuvelin have different roles in the down-regulation of hepcidin expression. J Biol Chem 2010; 285: 39021-8.
11. Ens CA, Ahmed R, Zhang AS,. Neogenin interacts with matriptase-2 to facilitate heojuvelin cleavage. J Biol Chem 2012; 287: 35104-17.
12. Benyamin B, Ferreira MA, Willemsen G, et al. Common variants in TMPRSS6 are associated with iron status and erythrocyte volume. Nat Genet 2009; 41: 1173-5.
13. Chambers JC, Zhang W, Li Y, et al. Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet 2009; 41: 1170-2.
14. Ganesh SK, Zakai NA, van Rooij FJ, et al. Multiple loci influence erythrocyte phenotypes in the CHARGE consortium. Nat Genet 2009; 41: 1191-8.
15. Tanaka T, Roy CN, Yao W, et al. A genome-wide association analysis of serum iron concentrations. Blood 2010; 115: 94-6.
16. McLaren CE, McLachlan S, Garner CP, et al. Associations between single nucleotide polymorphisms in iron-related genes and iron status in multiethnic populations. PLoS One 2012; 7: e38339.
17. Miller LD, Coffman LG, Chou JW, et al. An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res 2011; 71: 6728-37.
18. Odet F, Verot A, Le Magueresse-Battistoni B,. The mouse testis is the source of various serine proteases and serine proteinase inhibitors (SERPINs): serine proteases and SERPINs identified in leydig cells are under gonadotropin regulation. Endocrinology 2006; 147: 4374-83.
19. Overall CM, Tam EM, Kappelhoff R, et al. Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors. Biol Chem 2004; 385: 493-504.
20. Parr C, Sanders AJ, Davies G, et al. Matriptase-2 inhibits breast tumor growth and invasion and correlates with favorable prognosis for breast cancer patients. Clin Cancer Res 2007; 13: 3568-76.
21. Sanders AJ, Parr C, Martin TA, et al. Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells in vitro and in vivo and affects FAK and paxillin localisation. J Cell Physiol 2008; 216: 780-9.
22. Hartikainen JM, Tuhkanen H, Kataja V, et al. Refinement of the 22q12-q13 breast cancer-associated region: evidence of TMPRSS6 as a candidate gene in an eastern Finnish population. Clin Cancer Res 2006; 12: 1454-62.
23. Hartikainen J, Tuhkanen H, Kataja V, et al. An autosome-wide scan for linkage disequilibrium based association in sporadic breast cancer cases in Eastern Finland; three regions found. Cancer Epidemiol Biomarkers Prev 2005; 14: 75-80.
24. Pellikainen MJ, Pekola TT, Ropponen KM, et al. p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis. J Clin Pathol 2003; 56: 214-20.
25. Vandenplas S, Wiid I, Grobler-Rabie A, et al. Blot hybridisation analysis of genomic DNA. J Med Genet 1984; 21: 164-72.
26. Kauppinen JM, Kosma VM, Soini Y, et al. ST14 gene variant and decreased matriptase protein expression predict poor breast cancer survival. Cancer Epidemiol Biomarkers Prev 2010; 19: 2133-42.
27. Nykopp TK, Rilla K, Sironen R, et al. Expression of hyaluronan synthases (HAS1-3) and hyaluronidases (HYAL1-2) in serous ovarian carcinomas: inverse correlation between HYAL1 and hyaluronan content. BMC Cancer 2009; 9: 143.
28. McNeill RE, Miller N, Kerin MJ,. Evaluation and validation of candidate endogenous control genes for real-time quantitative PCR studies of breast cancer. BMC Mol Biol 2007; 8: 107.
29. Delbini P, Vaja V, Graziadei G, et al. Genetic variability of TMPRSS6 and its association with iron deficiency anaemia. Br J Haematol 2010; 151: 281-4.
30. Jegga AG, Gowrisankar S, Chen J, et al. PolyDoms: a whole genome database for the identification of non-synonymous coding SNPs with the potential to impact disease. Nucleic Acids Res 2007; 35: D700-D706.
31. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248-9.
32. Allione F, Eisinger F, Parc P, et al. Loss of heterozygosity at loci from chromosome arm 22Q in human sporadic breast carcinomas. Int J Cancer 1998; 75: 181-6.
33. Iida A, Kurose K, Isobe R, et al. Mapping of a new target region of allelic loss to a 2-cM interval at 22q13.1 in primary breast cancer. Genes Chromosomes Cancer 1998; 21: 108-12.
34. Castells A, Gusella JF, Ramesh V, et al. A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers. Cancer Res 2000; 60: 2836-9.
35. Hirano A, Emi M, Tsuneizumi M, et al. Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer. Clin Cancer Res 2001; 7: 876-82.
36. Lakhal S, Schodel J, Townsend AR, et al. Regulation of type II transmembrane serine proteinase TMPRSS6 by hypoxia-inducible factors: new link between hypoxia signaling and iron homeostasis. J Biol Chem 2011; 286: 4090-7.
37. Lopez-Otin C, Matrisian LM,. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007; 7: 800-8.
38. Alarmo EL, Kallioniemi A,. Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis? Endocr Relat Cancer 2010; 17: R123-R139.
39. Partanen JI, Tervonen TA, Myllynen M, et al. Tumor suppressor function of liver kinase B1 (Lkb1) is linked to regulation of epithelial integrity. Proc Natl Acad Sci USA 2012; 109: E388-E397.
40. List K, Kosa P, Szabo R, et al. Epithelial integrity is maintained by a matriptase-dependent proteolytic pathway. Am J Pathol 2009; 175: 1453-63.